SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001140361-20-029595
Filing Date
2020-12-28
Accepted
2020-12-28 16:05:12
Documents
1
Group Members
CROWN MANAGED ACCOUNTS SPCINVESTMENT OPPORTUNITIES 3SPCLMA SPC ON BEHALF OF MAP 98 SEGREGATED PORTFOLIOOCEANA MASTER FUND LTD.PENTWATER CREDIT MASTER FUND LTD.PENTWATER EQUITY OPPORTUNITIES MASTER FUND LTD.PENTWATER MERGER ARBITRAGE MASTER FUND LTD.PENTWA

Document Format Files

Seq Description Document Type Size
1 SC 13D brhc10018383_sc13d.htm SC 13D 496275
  Complete submission text file 0001140361-20-029595.txt   498294
Mailing Address 1001 10TH AVENUE SOUTH SUITE 216 NAPLES FL 34102
Business Address 1001 10TH AVENUE SOUTH SUITE 216 NAPLES FL 34102 239-384-9750
Pentwater Capital Management LP (Filed by) CIK: 0001425851 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE
Type: SC 13D

Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Subject) CIK: 0001661460 (see all company filings)

IRS No.: 472846548 | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91606 | Film No.: 201418431
SIC: 2836 Biological Products, (No Diagnostic Substances)